0QFD Stock Overview
A biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0QFD from our risk checks.
Moderna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$128.30 |
| 52 Week High | US$131.60 |
| 52 Week Low | US$58.73 |
| Beta | 1.56 |
| 1 Month Change | 29.73% |
| 3 Month Change | 57.64% |
| 1 Year Change | 7.01% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -6.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QFD | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 15.7% | 1.9% | 0.5% |
| 1Y | 7.0% | -20.4% | 6.3% |
Return vs Industry: 0QFD exceeded the UK Biotechs industry which returned -20.4% over the past year.
Return vs Market: 0QFD matched the UK Market which returned 6.3% over the past year.
Price Volatility
| 0QFD volatility | |
|---|---|
| 0QFD Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0QFD's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0QFD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5,600 | Stephane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
| 0QFD fundamental statistics | |
|---|---|
| Market cap | €49.78b |
| Earnings (TTM) | -€5.50b |
| Revenue (TTM) | €4.75b |
10.7x
P/S Ratio-9.2x
P/E RatioIs 0QFD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QFD income statement (TTM) | |
|---|---|
| Revenue | US$5.15b |
| Cost of Revenue | US$8.77b |
| Gross Profit | -US$3.62b |
| Other Expenses | US$2.35b |
| Earnings | -US$5.97b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -15.57 |
| Gross Margin | -70.27% |
| Net Profit Margin | -115.82% |
| Debt/Equity Ratio | 0% |
How did 0QFD perform over the long term?
See historical performance and comparison